Citation: | LEI Jiamin, HOU Ruihong, MI Liangyu, ZHANG Liyun, GAO Jinfang, XU Ke. Influencing factors analysis of systemic lupus erythematosus with osteonecrosis[J]. Chinese Journal of General Practice, 2024, 22(5): 750-753. doi: 10.16766/j.cnki.issn.1674-4152.003495 |
[1] |
张嵩, 谢长好, 陈琳洁. 女性系统性红斑狼疮合并膝关节骨梗死的临床分析[J]. 中华全科医学, 2020, 18(7): 1103-1106. doi: 10.16766/j.cnki.issn.1674-4152.001439
HANG S, XIE C H, CHEN L J. Clinical analysis of bone infarction of knee joint with female systemic lupus erythematosus[J]. Chinese Journal of General Practice, 2020, 18(7): 1103-1106. doi: 10.16766/j.cnki.issn.1674-4152.001439
|
[2] |
KANEKO K, CHEN H, KAUFMAN M, et al. Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients[J]. Clin Transl Med, 2021, 11(10): e526. DOI: 10.1002/ctm2.526.
|
[3] |
李宁宁, 陈奕均, 冷晓梅, 等. 系统性红斑狼疮并发骨坏死118例临床特点及危险因素分析[J]. 中华内科杂志, 2021, 60(8): 744-750. doi: 10.3760/cma.j.cn112138-20200916-00818
LI N N, CHEN Y J, LENG X M. Analysis of clinical characteristics and risk factors of 118 cases of systemic lupus erythematosus complicated with osteonecrosis[J]. Chinese Journal of Internal Medicine, 2021, 60(8): 744-750. doi: 10.3760/cma.j.cn112138-20200916-00818
|
[4] |
KALLAS R, LI J, PETRI M. Predictors of osteonecrosis in systemic lupus erythematosus: a prospective cohort study[J]. Arthritis Care Res(Hoboken), 2022, 74(7): 1122-1132. doi: 10.1002/acr.24541
|
[5] |
HISADA R, KATO M, OHNISHI N, et al. Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus[J]. Rheumatology(Oxford), 2019, 58(4): 645-649. doi: 10.1093/rheumatology/key365
|
[6] |
WEI Q, ZHOU M, LIU J, et al. Relationship between osteonecrosis and antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review protocol[J]. BMJ Open, 2021, 11(7): e46163. DOI: 10.1136/bmjopen-2020-046163.
|
[7] |
ARINGER M, COSTENBADER K, DAIKH D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9): 1151-1159. DOI: 10.1136/annrheumdis-2018-214819.
|
[8] |
GLADMAN D D, IBANEZ D, UROWITZ M B. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2): 288-291.
|
[9] |
SUN S, WANG Q, GONG Y, et al. Multifocal osteonecrosis affecting all four limbs in systemic lupus erythematosus: a case report[J]. Exp Ther Med, 2019, 18(4): 2475-2478.
|
[10] |
LESPASIO M J, SODHI N, MONT M A. Osteonecrosis of the hip: a primer[J]. Perm J, 2019, 23: 18-100.
|
[11] |
ZHENG Y, ZHENG Z, ZHANG K, et al. Osteonecrosis in systemic lupus erythematosus: systematic insight from the epidemiology, pathogenesis, diagnosis and management[J]. Autoimmun Rev, 2022, 21(2): 102992. DOI: 10.1016/j.autrev.2021.102992.
|
[12] |
LONG Y, ZHANG S, ZHAO J, et al. Risk of osteonecrosis in systemic lupus erythematosus: an 11-year Chinese single-center cohort study[J]. Lupus, 2021, 30(9): 1459-1468. doi: 10.1177/09612033211021166
|
[13] |
曲立阳, 李建军. 选择性免疫抑制剂对骨代谢影响的研究进展[J]. 中国医药科学, 2022, 12(11): 57-60. doi: 10.3969/j.issn.2095-0616.2022.11.015
QYU L Y, LI J J. Research progress on the impacts of selective immunosuppressants on bone metabolism[J]. China Medicine and Pharmacy, 2022, 12(11): 57-60. doi: 10.3969/j.issn.2095-0616.2022.11.015
|
[14] |
JIN W, YANG X, LU M. Juvenile-onset multifocal osteonecrosis in systemic lupus erythematosus: a case report[J]. Medicine(Baltimore), 2021, 100(2): e24031. DOI: 10.1097/MD.0000000000024031.
|
[15] |
ATTARDO S, MUSUMECI O, VELARDO D, et al. Statins neuromuscular adverse effects[J]. Int J Mol Sci, 2022, 23(15): 8364. DOI: 10.3390/ijms23158364.
|
[16] |
CRISAN E, PATIL V K. Neuromuscular complications of statin therapy[J]. Curr Neurol Neurosci Rep, 2020, 20(10): 47. DOI: 10.1007/s11910-020-01064-0.
|
[17] |
CAMERINO G M, TARANTINO N, CANFORA I, et al. Statin-induced myopathy: translational studies from preclinical to clinical evidence[J]. Int J Mol Sci, 2021, 22(4): 2070. DOI: 10.3390/ijms22042070.
|
[18] |
INDIRLI R, LANZI V, MANTOVANI G, et al. Bone health in functional hypothalamic amenorrhea: what the endocrinologist needs to know[J]. Front Endocrinol(Lausanne), 2022, 13: 946695. DOI: 10.3389/fendo.2022.946695.
|
[19] |
HERRADA A A, ESCOBEDO N, IRURETAGOYENA M, et al. Innate immune cells'contribution to systemic lupus erythematosus[J]. Front Immunol, 2019, 10: 772. DOI: 10.3389/fimmu.2019.00772.
|
[20] |
MA J, GE J, GAO F, et al. The role of immune regulatory cells in nontraumatic osteonecrosis of the femoral head: a retrospective clinical study[J]. Biomed Res Int, 2019, 2019: 1302015. DOI: 10.1155/2019/1302015.
|
[21] |
侯晓睿, 黄钊霞, 易夏玉, 等. NKT细胞在MRSA感染性肺炎中作用的初步研究[J]. 中国免疫学杂志, 2023, 39(9): 1803-1808. doi: 10.3969/j.issn.1000-484X.2023.09.003
HOU X R, HUANG Z X, YI X Y, et al. Preliminary study on role of NKT cells in MRSA infectious pneumonia[J]. Chinese Journal of Immunology, 2023, 39(9): 1803-1808. doi: 10.3969/j.issn.1000-484X.2023.09.003
|
[22] |
ALMEIDA J S, CASANOVA J M, SANTOS-ROSA M, et al. Natural killer T-like cells: immunobiology and role in disease[J]. Int J Mol Sci, 2023, 24(3): 2743. DOI: 10.3390/ijms24032743.
|
[23] |
LI J, YU T T, YAN H C, et al. T cells participate in bone remodeling during the rapid palatal expansion[J]. FASEB J, 2020, 34(11): 15327-15337. doi: 10.1096/fj.202001078R
|
[24] |
FAVALORO E J, PASALIC L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants[J]. Res Pract Thromb Haemost, 2022, 6(2): e12676. DOI: 10.1002/rth2.12676.
|
[25] |
DEVREESE K, DE GROOT P G, DE LAAT B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation[J]. J Thromb Haemost, 2020, 18(11): 2828-2839. doi: 10.1111/jth.15047
|
[26] |
JIANG W, HU J W, HE X R, et al. Statins: a repurposed drug to fight cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 241. DOI: 10.1186/s13046-021-02041-2.
|